Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02978222
Recruitment Status : Terminated (Futility analysis did not support continuation of the trial)
First Posted : November 30, 2016
Last Update Posted : February 20, 2020
Information provided by (Responsible Party):
Marker Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : January 15, 2020
Actual Study Completion Date : January 15, 2020